Skip to main content

DESARROLLO Y EVALUACION DE UNA HERRAMIENTA DE MHEALTH QUE UTILIZA LA INTELIGENCIA ARTIFICIAL PARA FORMULAR RECOMENDACIONES TERAPEUTICAS FARMACOLOGICAS PARA EL TRATAMIENTO DEL TDAH

PI19/00375

•
Funding agency name Instituto de Salud Carlos III
Funding agency acronym ISCIII
Program Programa Estatal de Generación de Conocimiento y Fortalecimiento del Sistema Español de I+D+I
Subprogram Subprograma Estatal de Generación de Conocimiento
Call Proyectos de Investigación en Salud
Call year 2019
State Plan 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre UNIVERSIDAD DE GERONA
Execution centre UNIVERSIDAD DE GERONA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

APPRAISE-RS, Automated, updated, participatory, and personalized treatment recommender systems based on GRADE methodology

  • López, Beatriz|||0000-0001-9210-0073
  • Raya, Oscar|||0000-0002-0420-3038
  • Baykova, Evgenia
  • Saez, Marc|||0000-0003-1882-0157
  • Rigau, David|||0000-0003-0828-4872
  • Cunill, Ruth|||0000-0003-3247-393X
  • Mayoral, Sacramento
  • Carrion, Carme|||0000-0003-1479-7551
  • Serrano, Domènec
  • Castells Cervelló, Xavier|||0000-0002-2619-7273
Clinical practice guidelines (CPGs) have become fundamental tools for evidence-based medicine (EBM). However, CPG suffer from several limitations, including obsolescence, lack of applicability to many patients, and limited patient participation. This paper presents APPRAISE-RS, which is a methodology that we developed to overcome these limitations by automating, extending, and iterating the methodology that is most commonly used for building CPGs: the GRADE methodology. APPRAISE-RS relies on updated information from clinical studies and adapts and automates the GRADE methodology to generate treatment recommendations. APPRAISE-RS provides personalized recommendations because they are based on the patient's individual characteristics. Moreover, both patients and clinicians express their personal preferences for treatment outcomes which are considered when making the recommendation (participatory). Rule-based system approaches are used to manage heuristic knowledge. APPRAISE-RS has been implemented for attention deficit hyperactivity disorder (ADHD) and tested experimentally on 28 simulated patients. The resulting recommender system (APPRAISE-RS/TDApp) shows a higher degree of treatment personalization and patient participation than CPGs, while recommending the most frequent interventions in the largest body of evidence in the literature (EBM). Moreover, a comparison of the results with four blinded psychiatrist prescriptions supports the validation of the proposal. APPRAISE-RS is a valid methodology to build recommender systems that manage updated, personalized and participatory recommendations, which, in the case of ADHD includes at least one intervention that is identical or very similar to other drugs prescribed by psychiatrists.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Placebo Response and Its Predictors in Attention Deficit Hyperactivity Disorder, A Meta-Analysis and Comparison of Meta-Regression and MetaForest

  • Castells Cervelló, Xavier|||0000-0002-2619-7273
  • Saez, Marc|||0000-0003-1882-0157
  • Barcheni, Maghie|||0000-0002-5093-3330
  • Cunill, Ruth|||0000-0003-3247-393X
  • Serrano Sarbosa, Domènec|||0000-0001-8214-2448
  • López, Beatriz|||0000-0001-9210-0073
  • van Lissa, Caspar J.|||0000-0002-0808-5024
Background: High placebo response in attention deficit hyperactivity disorder (ADHD) can reduce medication-placebo differences, jeopardizing the development of new medicines. This research aims to (1) determine placebo response in ADHD, (2) compare the accuracy of meta-regression and MetaForest in predicting placebo response, and (3) determine the covariates associated with placebo response. Methods: A systematic review with meta-analysis of randomized, placebo-controlled clinical trial investigating pharmacological interventions for ADHD was performed. Placebo response was defined as the change from baseline in ADHD symptom severity assessed according to the 18-item, clinician-rated, DSM-based rating scale. The effect of study design-, intervention-, and patient-related covariates in predicting placebo response was studied by means of meta-regression and MetaForest. Results: Ninety-four studies including 6614 patients randomized to placebo were analyzed. Overall, placebo response was -8.9 points, representing a 23.1% reduction in the severity of ADHD symptoms. Cross-validated accuracy metrics for meta-regression were R = 0.0012 and root mean squared error = 3.3219 for meta-regression and 0.0382 and 3.2599 for MetaForest. Placebo response among ADHD patients increased by 63% between 2001 and 2020 and was larger in the United States than in other regions of the world. Conclusions: Strong placebo response was found in ADHD patients. Both meta-regression and MetaForest showed poor performance in predicting placebo response. ADHD symptom improvement with placebo has markedly increased over the last 2 decades and is greater in the United States than the rest of the world.